|
|
 |
|
Viewing report
|
|
|
|
Biomed Outsourcing Report: An Overview of the Life Sciences and Outsourcing Landscape in India: Spotlight on Bangalore
CanBiotech, March 2007, Pages: 54
Countries that can offer lower costs during research and development while ensuring adequate protection of intellectual property and adherence to global regulatory standards are well positioned to attract the attention of large biopharmaceutical companies looking to outsource drug discovery and/or development.
India is poised to make big contributions to the global healthcare industry. The country is emerging as a competitive base for several segments of the R&D value chain, especially in late discovery, preclinical, and clinical development.
Major multinationals have established subsidiaries in India. U.S. and European companies are collaborating with Indian firms to develop new drugs and vaccines, to conduct clinical trials and toxicity studies, to perform molecular modeling and lead optimization, to provide computer services such as bioinformatics, and to develop industrial production processes for new drug ingredients. Similarly, venture capitalists from the U.S. and Singapore are helping to fund start-up biotechnology companies in India.
Indian companies are also set to tap into the global biopharmaceutical outsourcing market. These companies are increasingly moving into the developed market and transitioning from bulk drugs to formulation exports. Indian companies are also expected to produce many of the top drop drugs that are scheduled to lose patent protection over the next few years. India will not only be accessing the generics market, but the research focus of many large companies has shifted toward the discovery of new chemicals-providing the skill set necessary for upstream outsourcing.
Bangalore is fast becoming one of major hubs of the biotechnology industry in India. With Bangalore firmly established as the country's premier IT and biotech hub, it comes as no surprise that the city is home to India's largest biocluster. Approximately 158 of the 320 biotech companies are based there, with total revenues of Rs 1,400 crore. Further, fifty-five per cent of India's biotechnology companies are located in Karnataka. The Government of Karnataka is committed to establishing a biotechnology corridor for the development of the biotechnology industry in Karnataka.
Contract Research Organizations have great potential to function as export
oriented units and are comparable in their activity to the software development activities in the IT sector. Software services were outsourced by large overseas IT companies, starting initially with the sub-contracting software development of small modules of complex software and a decade later, the Indian IT sector is now capable of handling the entire software development process-the primary reason for the prolific growth in the IT sector. Contract research in biotechnology offers the same growth potential and the Government of Karnataka is firmly committed to supporting these organizations.
Through the use of brief case studies we provide an overview of the activities of several multinational companies located in Bangalore as well as the current state of affair of contract research outsourcing in Bangalore. Contact information is provided for these companies including key executive names.
Customers who bought this item also bought
India CRO Directory & Industry Tracker 2012
Biotechnology in India - An Indian Market Report
India: Pharmaceutical and Biotechnology Opportunities
Advances in Biopharmaceutical Technology in India
Proteomics - Global Strategic Business Report
Bioinformatics Outsourcing for Life Sciences: India Opportunity
Agricultural Biotechnology - Global Strategic Business Report
Directory of Top 60 Biopharmaceutical Manufacturers in India
Guide to Pharmaceutical Outsourcing in China: A Handbook for Pharmaceutical and Biotechnology Companies Planning to Outsource to China
Bioinformatics - Global Strategic Business Report
|
|
|
|
